Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1896-1900

  Iwadate, Y ^a   Fujimoto, S ^b   Namba, H ^c   Yamaura, A ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Chemosensitivity test; Glioblastoma; Glioma; Survival

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CARBOQUONE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NIMUSTINE; PEPLEOMYCIN; PIRARUBICIN; RANIMUSTINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZINOSTATIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR CELL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0346121829     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601376     Document Type: Article

References (27)

1. Alberts D, Chen HSG (1980) Tabular Summary of Pharmacokinetic Parameters Relevant to In Vitro Drug Assay. New York: Alan R Liss pp 351-359
2. Alonso K (1984) Human tumor stem cell assay. A prospective clinical trial. Cancer 54: 2475-2479
3. Cortazar P, Gazdar AF, Woods E, Russel E, Steinberg SM, Williams J, Ihde DC, Johnson BE (1997) Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3: 741-747
4. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147
5. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808
6. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC (1990) Correlation of in vitro drug-sensitivity testing with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 82: 117-124
7. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44: 1479-1483
8. Iwadate Y, Fujimoto S, Sueyoshi K, Namba H, Tagawa M, Yamaura A (1997) Prediction of drug cytotoxicity in 9L rat brain tumor by using flow cytometry with a deoxyribonucleic acid-binding dye. Neurosurgery 40: 782-788
9. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69: 236-240
10. Iwadate Y, Fujimoto S, Yamaura A (2002) Differential chemosensitivity in human intra-cerebral gliomas measured by flow cytometric DNA analysis. Int J Mol Med 10: 187-192
11. Iwadate Y, Mochizuki S, Fujimoto S, Namba H, Sakiyama S, Tagawa M, Yamaura A (2000) Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents. Int J Oncol 17: 501-505
12. Iwadate Y, Namba H, Sueyoshi K (1995) Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Neurol Med Chir (Tokyo) 35: 598-603
13. Iwadate Y, Tagawa M, Fujimoto S, Hirose M, Namba H, Sueyoshi K, Sakiyama S, Yamaura A (1998) Mutation of the p53 gene in human astrocytic tumors correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer 77: 547-551
14. James CD, Olson JJ (1995) Molecular genetics and molecular biology advances in brain tumors. Curr Opin Oncol 8: 188-195
15. Kimmel DW, Shapiro JR, Shapiro WR (1987) In vitro drug sensitivity testing in human gliomas. J Neurosurg 66: 161-171
16. Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324
17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279
19. Medical Research Council Brain Tumour Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J Clin Oncol 19: 509-518
20. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM (2001) Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61: 6885-6891
21. Rosenblum ML, Gerosa MA, Wilson CB, Barger GR, Pertuiset BF, de Tribolet N, Dougherty DV (1983) Stem cell studies of human malignant brain tumors. J Neurosurg 58: 170-176
22. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321-1327
23. Sekiya S, Iijima N, Oosaki T, Takamizawa H, Tokita H (1991) A newly developed in vitro chemosensitivity test (nuclear damage assay): application to ovarian cancer. Gynecol Oncol 40: 138-143
24. Shapiro WR (1999) Current therapy for brain tumors: back to the future. Arch Neurol 56: 429-432
25. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi T, Matsutani M, Nomura K (1986) Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64: 53-57
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
27. Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart MJ, Colombo N, Muggia FM (1990) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82: 110-116